This filing confirms GSK is steadily executing its existing buyback program. No new authorization or change in pace is indicated. Traders should monitor future 6-K filings for cumulative buyback progress and any updates to the program's size or duration.
GSK drugs
GSK drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 15 $52.23entry
- T+1 · 5mo ago −0.02%α +0.58% · $52.22
- T+5 · 5mo ago −2.85%α −1.47% · $50.74
- T+20 · 4mo ago +0.11%α +0.86% · $52.29
- T+60 · 2mo ago −6.89%α −7.90% · $48.63
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK filed a routine 6-K disclosing weekly share repurchases under its existing buyback program. The company bought ~1.1M shares over five days in June 2026 at an average price of ~1,930 GBp, continuing the program announced on May 11, 2026. This is a standard periodic update with no new strategic or financial information.
Key Facts
- Purchased 225,237 shares on June 8, 228,524 on June 9, 222,449 on June 10, 220,242 on June 11, and 215,972 on June 12, 2026.
- Volume-weighted average prices ranged from 1,882.23 GBp to 1,983.00 GBp per share.
- Since May 11, 2026, GSK has repurchased a total of 7,346,236 ordinary shares.
- After these purchases, GSK holds 268,724,522 shares in treasury (6.64% of voting rights) and has 4,047,527,077 shares in issue (excluding treasury).
Financial Impact
Approximately £21.2M spent on repurchases during the reported week (based on VWAP and share counts), representing ~0.02% of market cap. Cumulative program spend since May 11 is not disclosed but is a fraction of the overall buyback authorization.
Risk Factors
- None material from this filing; buyback execution is routine and within announced parameters.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-005975 |
| Document: 0001654954-26-005975-index-headers.html | 0001654954-26-005975 |
| Document: 0001654954-26-005975-index.html | 0001654954-26-005975 |
| Document: 0001654954-26-005975.txt | 0001654954-26-005975 |
Track record
64 reports on GSK
9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers